Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Afatinib - Boehringer Ingelheim

X
Drug Profile

Afatinib - Boehringer Ingelheim

Alternative Names: Afatinib dimaleate; BIBW 2992 MA2; BIBW-2992; Gilotrif; Giotrif; Tomtovok; Tovok; Xovoltib

Latest Information Update: 03 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics; Quinazolines; Radiation-sensitising agents; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer; CNS cancer; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase III Breast cancer; Head and neck cancer
  • Phase II Chordoma; Glioma; HER2 negative breast cancer; Oesophageal cancer; Urogenital cancer
  • Phase I/II Neuroectodermal tumours; Rhabdomyosarcoma
  • No development reported Colorectal cancer; Gastric cancer; Glioblastoma; Pancreatic cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 06 Mar 2024 Boehringer Ingelheim completes a phase III trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, First-line therapy) (PO, Tablet) in Hungary, Spain and the Czech Republic Italy, Austria, Australia, Greece, Israel, Poland, Portugal, Russia and Switzerland(EudraCT2009-017661-34) (NCT01853826)
  • 22 Mar 2023 Boehringer Ingelheim completes phase II DARWIN1 trial for Non-small cell lung cancer in United Kingdom (NCT02183883)
  • 20 Feb 2023 Memorial Sloan Kettering Cancer Center completes a phase II trial in Esophagogastric cancer in the USA (NCT01522768)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top